AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36453656 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) <120 mmHg at age 40-43 years
Number of subjects: 2424
Study 36453656 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in SBP during the 25-year follow-up
Number of subjects: 2424
Study 36453667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates intervention, details on dosage and duration not available
Number of subjects: 0
Study 36453699 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary vs No treatment
Number of subjects: 2983
Study 36453699 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary vs Vaginal progesterone
Number of subjects: 2983
Study 36453699 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary vs Cervical cerclage
Number of subjects: 2983
Study 36454054 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory and/or immunosuppressive (IM/IS) drugs
Number of subjects: 1672
Study 36454054 — intervention group
Group type: COMPARATOR
Intervention: No treatment with IM/IS drugs (Control)
Number of subjects: 1672
Study 36454186 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 0
Study 36454322 — intervention group
Group type: EXPERIMENTAL
Intervention: Decalcified choroidal osteoma complicated by MNV
Number of subjects: 28
Study 36454322 — intervention group
Group type: EXPERIMENTAL
Intervention: Decalcified choroidal osteoma
Number of subjects: 28
Study 36454322 — intervention group
Group type: COMPARATOR
Intervention: Calcified choroidal osteoma
Number of subjects: 28
Study 36454567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge HIV care continuum intervention
Number of subjects: 1225
Study 36454631 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological evidence suggesting recent EBV reactivation (early antigen-diffuse IgG positivity)
Number of subjects: 280
Study 36454631 — intervention group
Group type: EXPERIMENTAL
Intervention: Underlying HIV infection
Number of subjects: 280
Study 36454631 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic evidence of prior CMV infection
Number of subjects: 280
Study 36455049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0
Study 36455189 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 322
Study 36455228 — intervention group
Group type: EXPERIMENTAL
Intervention: Trotabresib 30 mg/day on days 1-4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery
Number of subjects: 20
Study 36455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib 60 mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840 mg every 2 weeks (Cohort A)
Number of subjects: 103
Study 36455412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib for the first 14 days prior to initiation of atezolizumab on cycle 1 day 15 (Cohort B)
Number of subjects: 103
Study 36455699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO) worn for 3 months
Number of subjects: 7
Study 36455999 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals' perceptions and attitudes regarding children with early childhood caries and their families
Number of subjects: 0
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age less than 18 years
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Muslim
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: First pregnancy
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple births
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Male child
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education >5 years
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal height ≥150 cm
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Being from wealthier families
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bleeding
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (BP) in third trimester
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: High diastolic BP in third trimester
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory problem in third trimester
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Having poor appetite, nausea and vomiting in second trimester
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Having poor appetite, nausea and vomiting in third trimester
Number of subjects: 40119
Study 36456014 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weight gain from second to third trimester
Number of subjects: 40119
Study 36456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin prophylaxis
Number of subjects: 645
Study 36456026 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 645
Study 36456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 645
Study 36456066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamically-guided management using an implanted pulmonary artery pressure sensor
Number of subjects: 1000
Study 36456066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study 36456068 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAD implantation
Number of subjects: 2200
Study 36456072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (Sac/Val)
Number of subjects: 794
Study 36456101 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood RNA-sequencing (RNA-seq)
Number of subjects: 23
Study 36456101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sixteen DE lncRNAs
Number of subjects: 23
Study 36456193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 36456200 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-leucine (NALL) administered orally at 4 g/d for patients ≥13 years, weight-tiered doses for patients 6-12 years for 6 weeks.
Number of subjects: 30
Study 36456200 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-leucine (NALL)
Number of subjects: 30
Study 36456573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m) in combination with standard chemotherapy
Number of subjects: 233
Study 36456573 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy (NAC)
Number of subjects: 233
Study 36456835 — intervention group
Group type: EXPERIMENTAL
Intervention: LNA043 (angiopoietin-like 3 derivative)
Number of subjects: 0
Study 36457012 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-COPD subjects
Number of subjects: 199
Study 36457012 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 199
Study 36457567 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) group
Number of subjects: 48
Study 36457567 — intervention group
Group type: COMPARATOR
Intervention: Opioid-based anesthesia (OBA) group
Number of subjects: 48
Study 36457575 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha particle-emitting isotopes (Radium-223, Actinium-225, Thorium-227)
Number of subjects: 0
Study 36457825 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic surgery in aged mice
Number of subjects: 0
Study 36457825 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in humans
Number of subjects: 0
Study 36457825 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery in mice
Number of subjects: 0
Study 36457860 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP-AF® (200 mg/day for 4 weeks)
Number of subjects: 37
Study 36457860 — intervention group
Group type: COMPARATOR
Intervention: Control (4 weeks without EPP-AF®)
Number of subjects: 37
Study 36458416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 60
Study 36458608 — intervention group
Group type: EXPERIMENTAL
Intervention: RAADS-R-DK
Number of subjects: 600
Study 36458659 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning approach using images from a magnetic endoscopic imaging (MEI) device for 5-class colorectal segment division
Number of subjects: 1196
Study 36458659 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning approach using images from a magnetic endoscopic imaging (MEI) device for 2-class colorectal segment division
Number of subjects: 1196
Study 36458825 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Number of subjects: 32
Study 36458825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg)
Number of subjects: 32
Study 36459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 17
Study 36459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 17
Study 36459100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training; details on dosage and duration not available.
Number of subjects: 0
Study 36459100 — intervention group
Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study 36459227 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Number of subjects: 0
Study 36459227 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 0
Study 36459243 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 63
Study 36459255 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib FBS 1050 mg twice daily
Number of subjects: 179
Study 36459255 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib SDD 750 mg twice daily
Number of subjects: 179
Study 36459255 — intervention group
Group type: EXPERIMENTAL
Intervention: Glesatinib (various formulations)
Number of subjects: 179
Study 36459284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib 60 mg orally twice daily in 28-day continuous cycles
Number of subjects: 88
Study 36459284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamiparib
Number of subjects: 88
Study 36459310 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D replacement (REP)
Number of subjects: 276
Study 36459310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without persistent ICD indication at REP
Number of subjects: 276
Study 36459310 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors of sVAE
Number of subjects: 276
Study 36459469 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (n = 71)
Number of subjects: 131
Study 36459469 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 60)
Number of subjects: 131
Study 36459629 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36459673 — intervention group
Group type: EXPERIMENTAL
Intervention: Axatilimab (3 mg/kg given once every 4 weeks)
Number of subjects: 40
Study 36459673 — intervention group
Group type: EXPERIMENTAL
Intervention: Axatilimab
Number of subjects: 40
Study 36459691 — intervention group
Group type: EXPERIMENTAL
Intervention: STRO-002
Number of subjects: 0
Study 36459691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin or Avastin
Number of subjects: 0
Study 36459917 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy at medium threshold
Number of subjects: 17
Study 36459917 — intervention group
Group type: EXPERIMENTAL
Intervention: aEEG
Number of subjects: 17
Study 36459917 — intervention group
Group type: COMPARATOR
Intervention: Direct Observation (DO)
Number of subjects: 17
Study 36459994 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of rhu-GM-CSF
Number of subjects: 81
Study 36459994 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 81
Study 36460211 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 132
Study 36460211 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain echocardiography
Number of subjects: 132
Study 36460211 — intervention group
Group type: COMPARATOR
Intervention: LGE-CMR
Number of subjects: 132
Study 36460331 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 200
Study 36460331 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool sample analysis for CoPEC detection and microbiota composition assessment
Number of subjects: 200
Study 36460331 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data and survival outcomes collection
Number of subjects: 200
Study 36460344 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36460537 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose HPV vaccination program
Number of subjects: 0
Study 36460537 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose HPV vaccination program
Number of subjects: 0
Study 36460655 — intervention group
Group type: EXPERIMENTAL
Intervention: aP booster vaccination
Number of subjects: 0
Study 36460655 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36460761 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Neck System (FNS)
Number of subjects: 125
Study 36460794 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaganib 500 mg BID
Number of subjects: 13
Study 36460794 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaganib (up to 750 mg BID)
Number of subjects: 13
Study 36460794 — intervention group
Group type: EXPERIMENTAL
Intervention: Opaganib
Number of subjects: 13
Study 36460852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette syndrome
Number of subjects: 62
Study 36460967 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) cases treated by EMS
Number of subjects: 838
Study 36460967 — intervention group
Group type: COMPARATOR
Intervention: Utstein comparator group
Number of subjects: 838
Study 36461000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care (five sessions of symptom management and coping enhancement counseling by nurses)
Number of subjects: 360
Study 36461000 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring (control group)
Number of subjects: 360
Study 36461034 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 15773
Study 36461034 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 15773
Study 36461034 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Height Ratio (WHtR)
Number of subjects: 15773
Study 36461034 — intervention group
Group type: EXPERIMENTAL
Intervention: A Body Shape Index (ABSI)
Number of subjects: 15773
Study 36461061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 26709
Study 36461061 — intervention group
Group type: COMPARATOR
Intervention: Non-exclusive breastfeeding
Number of subjects: 26709
Study 36461061 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall exclusive breastfeeding rates over time
Number of subjects: 26709
Study 36461061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding following WHO guidelines publication
Number of subjects: 26709
Study 36461087 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) program
Number of subjects: 40
Study 36461134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (20-50 min, 3 times/week for 6 months)
Number of subjects: 96
Study 36461134 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity stretching (20-50 min, 3 times/week for 6 months)
Number of subjects: 96
Study 36461157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation for research procedures in CLN3 (28 anesthetic events)
Number of subjects: 47
Study 36461157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation for research procedures in GM1 (19 anesthetic events)
Number of subjects: 47
Study 36461157 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sedation outcomes for both conditions (47 anesthetic events)
Number of subjects: 47
Study 36461750 — intervention group
Group type: EXPERIMENTAL
Intervention: HF nurse intervention (n=53)
Number of subjects: 593
Study 36461750 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback combined with natriuretic peptide testing
Number of subjects: 593
Study 36461750 — intervention group
Group type: COMPARATOR
Intervention: Renin-angiotensin-aldosterone system inhibitors or beta-blockers
Number of subjects: 593
Study 36461912 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice Bran (RB) supplementation (15 g/day)
Number of subjects: 18
Study 36461912 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 36461942 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 0
Study 36462064 — intervention group
Group type: EXPERIMENTAL
Intervention: HD Grid high-density mapping catheter
Number of subjects: 20
Study 36462064 — intervention group
Group type: COMPARATOR
Intervention: 20-pole circumferential mapping catheter (CMC-20)
Number of subjects: 20
Study 36463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication of H. pylori
Number of subjects: 1824
Study 36463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Correa's steps III-V
Number of subjects: 1824
Study 36463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, OLGA stages ≥ I, OLGIM stages ≥ I
Number of subjects: 1824
Study 36463104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg and gemcitabine 1,250 mg/m²
Number of subjects: 36
Study 36463140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing observational cohort study
Number of subjects: 10000
Study 36463140 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up data collection
Number of subjects: 10000
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (poor)
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (lower-middle class)
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (high school)
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment (< high school)
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 25-34 years
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 35-50 years
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment in food services
Number of subjects: 0
Study 36463160 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment in healthcare and within home, and primiparity
Number of subjects: 0
Study 36463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support (PRS)
Number of subjects: 17
Study 36463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Treatment Drug Court (FTDC)
Number of subjects: 17
Study 36463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications for Opioid Use Disorder (MOUD)
Number of subjects: 17
Study 36463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurturing Parent Program (NPP)
Number of subjects: 17
Study 36463180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) once daily (OD) for 1 year
Number of subjects: 58
Study 36463180 — intervention group
Group type: COMPARATOR
Intervention: Placebo OD for 1 year
Number of subjects: 58
Study 36463214 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based program (PARTNER UP) providing access to oral pre-exposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) through syringe services programs (SSPs). Initial in-person visit followed by weekly telemedicine visits in month 1 and monthly visits until month 6.
Number of subjects: 17
Study 36463214 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits (PARTNER UP)
Number of subjects: 17
Study 36463214 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial in-person meeting
Number of subjects: 17
Study 36463214 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit schedule of PARTNER UP
Number of subjects: 17
Study 36463219 — intervention group
Group type: EXPERIMENTAL
Intervention: ARAT-VR
Number of subjects: 30
Study 36463457 — intervention group
Group type: EXPERIMENTAL
Intervention: PIVOT HD (PTC518)
Number of subjects: 0
Study 36463457 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNAL (pepinemab)
Number of subjects: 0
Study 36463457 — intervention group
Group type: EXPERIMENTAL
Intervention: SELECT HD
Number of subjects: 0
Study 36463457 — intervention group
Group type: EXPERIMENTAL
Intervention: uniQure AMT-130
Number of subjects: 0
Study 36463457 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBRANT HD
Number of subjects: 0
Study 36463540 — intervention group
Group type: EXPERIMENTAL
Intervention: O3® Regional Oximetry on quadriceps
Number of subjects: 26
Study 36463540 — intervention group
Group type: EXPERIMENTAL
Intervention: O3® Regional Oximetry on flank
Number of subjects: 26
Study 36463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Number of subjects: 20
Study 36463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum
Number of subjects: 20
Study 36463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position
Number of subjects: 20
Study 36463542 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cardiac index and stroke volume index
Number of subjects: 20
Study 36463561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib-based triple-drug therapy
Number of subjects: 320
Study 36464141 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg QD
Number of subjects: 988
Study 36464141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study 36464218 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 116